Ignite Creation Date:
2024-05-06 @ 12:15 AM
Last Modification Date:
2024-10-26 @ 10:47 AM
Study NCT ID:
NCT01528345
Status:
TERMINATED
Last Update Posted:
2016-07-11
First Post:
2012-01-31
Brief Title:
Trial Evaluating Dovitinib Combined With Fulvestrant in Postmenopausal Patients With HER2- and HR Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Multicenter Randomized Double Blind Placebo Controlled Phase II Trial Evaluating the Safety and Efficacy of Dovitinib Combined With Fulvestrant in Postmenopausal Patients With HER2- and HR Breast Cancer That Have Evidence of Disease Progression on or After Prior Endocrine Therapy
Status:
TERMINATED
Status Verified Date:
2016-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Slow and low enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is designed to enroll postmenopausal patients with locally advanced or metastatic HER2- and HR breast cancer not amenable to curative treatment by surgery or radiotherapy and whose disease has progressed on or after prior endocrine therapy
Patients must undergo molecular pre-screening prior to entry
Patients must undergo molecular pre-screening prior to entry
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2011-001230-42 | EUDRACT_NUMBER | None | None |